Cefotetan can cause severe immune hemolytic anemia that may persist long after the drug is discontinued. To study the binding of cefotetan to RBCs, patients who received cefotetan were followed and tested for the presence of antibody to cefotetan.
efotetan is a second-generation cephalosporin with a broad spectrum of activity against Gramnegative rods. It is commonly used for preoperative prophylaxis before abdominal surgery and Caesarian section. Like other cephalosporins, cefotetan can cause immune hemolytic anemia (IHA). Serologic studies have suggested that cefotetan is the most common cause of antibiotic-induced IHA. 1 A review of cefotetaninduced hemolytic anemia reported to the USFDA and the WHO identified 85 cases since 1985. 2 Of these cases, 76 percent were female, 59 percent had received the drug for surgical prophylaxis, 30 percent received the drug for 1 day or less, and 18 percent had a prior exposure to cefotetan. Fifteen fatalities were identified. Within the fatal cases of IHA, the treatment length ranged from 1 to 11 days. Eleven of the fatal cases had no prior history of exposure to the drug.
Cefotetan-induced IHA may occur several weeks after the last dose. 3, 4 We have previously observed prolonged hemolysis in cefotetan-induced IHA after withdrawal of the drug. Although cefotetan is know to have a plasma t 1/2 of 3 to 4 hours, 5 which is relatively long compared to other cephalosporins, the persistence of IHA for days or weeks is unexplained. We hypothesized that cefotetan may remain bound to RBCs after expected clearance of the drug from plasma. We have studied the binding of cefotetan to RBCs in vivo and in vitro to test this hypothesis.
MATERIALS AND METHODS
Inpatients receiving cefotetan at the University of Michigan Medical Center were identified from pharmacy C records. When there was any question of dosage, medication administration records were checked. Blood samples were obtained after routinely ordered hematology tests were performed. The Institutional Review Board of the University of Michigan Medical School approved the study.
Cefotetan-coated cells were prepared, as previously described, by incubation of 1 mL RBCs with 465 mg cefotetan disodium (AstraZeneca, Wilmington, DE) dissolved in 15 mL of boric acid buffer, pH 9.6 to 10, for 1 hour at 37 ∞ C. 6 Drug-coated RBCs were stored in Alsever's solution until used. For detection of cefotetan on RBCs, we used a previously characterized antibody from a patient with cefotetan-induced IHA (IgG titer = 250,000). For in-vitro studies, cefotetan disodium was prepared immediately before use in PBS pH 7.4. Five percent suspensions of normal donor RBCs were prepared in PBS. Serial twofold dilutions of cefotetan were prepared, taking into account the RBC diluent volume, with final concentrations of 100 to 0.39 m mol/L (62-0.24 mg/L). RBCs were incubated with drug for 1 hour at 37 ∞ C, washed with PBS, and tested with anticefotetan at 1 : 500 dilution by gel technique as above. Experiments were performed in three replicates using four different normal donor RBC samples. In some experiments, RBCs were pretreated with ficin, sialydase, or DTT according to published methods before incubation with cefotetan. 6 
RESULTS
Sixty patients receiving cefotetan were identified. All received intravenous doses of the drug. The total dosage range was 1 to 25 g (median, 2 g). The follow-up time ranged from 1 to 123 days (median, 18 days).
Twenty patients not receiving cefotetan were also tested. Seven patients received ceftriaxone, four received cefazolin, one received ceftazidime, and one received cefepime. One patient who received ceftriaxone had a positive test with both anticefotetan and 6-percent albumin. This patient had a 1+ positive DAT with anti-IgG, negative with anti-C3. She had a history of dematomyositis, rheumatoid arthritis, and chronic HBV infection. There was no history of cefotetan exposure. An RBC eluate was not performed. None of the others manifested a positive test with anticefotetan or 6-percent albumin.
All patients receiving cefotetan manifested a positive test of 1+ strength or greater with anticefotetan on the first sample obtained after with drug was begun. Positivity persisted for up to 98 days after the last dose was given (Fig.  1) . During the follow-up period, a negative sample was obtained on 15 patients. The first negative sample occurred at Day 30 to 123. Using the midpoint between the last positive and first negative to estimate the duration of positivity, we estimate that cefotetan remains RBCbound for 16.5 to 92 days (median, 67.5 days) (Fig. 2) .
During the follow-up period, five patients developed anticefotetan antibodies detectable in the plasma. Anticefotetan was first detected 5 to 78 days (median, 54 days) after the first dose. One of these patients had a previous documented exposure to cefotetan; however, complete records were not available for all patients. Chart reviews were performed. No patient had a clinically evident hemolytic reaction. All five patients had decreases in Hb level at the time that anticefotetan was detected from 0.1 to 1.7 g per dL (median, 1.2 g/dL). Serum bilirubin concentration was measured in three patients after anticefotetan was detected and was normal in all cases. Antibody titration was performed in one case. The anticefotetan titer was 2560. Three of these patients received prophylactic doses of 1 to 4 g, whereas the other two received 2 g per day for 10 and 12 days. There was no apparent difference between antibody producers and nonantibody producers in the dose of cefotetan administered (Fisher's exact test, p = 0.12).
Eight patients received RBC transfusions during the follow-up period for which paired pre-and posttransfusion samples were available. The transfusions occurred from 2 to 66 days after the last drug dose. In seven of these, there was no change in reactivity strength of the posttransfusion RBCs with anticefotetan, as compared to a pretransfusion sample. With one transfusion occurring 52 days after the last dose, the pretransfusion sample was 1+ with anticefotetan, and the posttransfusion sample did not react. No mixed-field reactivity was seen after any transfusion, including four cases where the pretransfusion reactivity was 3+ or greater.
We also performed in-vitro studies in an effort to determine which membrane proteins might be involved and the minimum concentration for cefotetan binding to RBC. At physiologic pH, 1+ reactivity occurred at approximately 1 m mol/L (Fig. 3) . Pretreatment of RBCs with ficin or DTT did not alter cefotetan binding (minimum positive concentration, 0.78 m mol/L). Sialydase pretreatment caused a slight diminution in agglutination strength (minimum concentration, 1.63 m mol/L).
DISCUSSION
These data indicate that cefotetan readily becomes tightly bound to RBCs when administered at prophylactic or therapeutic doses. After an intravenous dose of 1 g, the peak serum concentration is approximately 150 mg per L or 242 m mol/L. 5 This is well in excess of the minimal concentration of 1 m mol/L we found for in-vitro RBC binding. Cefotetan appears to remain bound to RBCs for most, if not all, of the life span of the cell. This markedly prolonged persistence may account for observed hemolytic reactions that continue for weeks after the drug is withdrawn.
In addition, we found that 5 of 60 patients (8%) in this study produced detectable anticefotetan. Although these patients had at most mild hemolysis, and none had a clinical reaction, this is a strikingly high rate of immune response. To our knowledge, this is the first study to prospectively identify immune responses to cefotetan. If further investigations confirm a high rate of antibody production, then testing previously exposed patients before administration of cefotetan again may be warranted.
We did not observe a dual cell population in patients who were transfused after the last dose of cefotetan. It is possible that our method was not sufficiently sensitive to detect a minor population of RBC that did not react with anticefotetan. Alternatively, it may be possible that transfused RBCs acquired cefotetan from previously coated cells in vivo. Further studies with highly sensitive methods such as flow cytometry will be necessary to distinguish between these possibilities.
The mechanism of cefotetan binding to the RBC membrane is unclear. Membrane proteins sensitive to ficin degradation, sialic acid residues, sulfhydryls, and free amines are not likely to be involved. A slight difference between untreated and sialydase-treated RBCs was observed. However, the preponder- ance of cefotetan binding is clearly not dependent on sialic acid.
We conclude from these data that cefotetan binds tightly to RBCs of patients given typical doses and that the drug persists on RBCs for about 9 weeks. Furthermore, the incidence of antibody production to cefotetan may be as high as 8 percent. Given the common use of cefotetan, there may be a substantial number of patients at risk of IHA if given a second dose of cefotetan.
